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The Journal of Immunology
Aerosol Delivery of a Candidate Universal Influenza Vaccine
Reduces Viral Load in Pigs Challenged with Pandemic H1N1
Virus
Sophie B. Morgan,*,1 Johanneke D. Hemmink,*,1 Emily Porter,† Ross Harley,†
Holly Shelton,* Mario Aramouni,‡ Helen E. Everett,x Sharon M. Brookes,x
Michael Bailey,† Alain M. Townsend,{ Bryan Charleston,* and Elma Tchilian*
Influenza Aviruses are amajor health threat to livestock and humans, causing considerable mortality, morbidity, and economic loss.
Current inactivated influenza vaccines are strain specific and new vaccines need to be produced at frequent intervals to combat
newly arising influenza virus strains, so that a universal vaccine is highly desirable. We show that pandemic H1N1 influenza virus in
which the hemagglutinin signal sequence has been suppressed (S-FLU), when administered to pigs by aerosol can induce CD4 and
CD8 T cell immune responses in blood, bronchoalveolar lavage (BAL), and tracheobronchial lymph nodes. Neutralizing Ab was not
produced. Detection of a BAL response correlated with a reduction in viral titer in nasal swabs and lungs, following challenge with
H1N1 pandemic virus. Intratracheal immunization with a higher dose of a heterologous H5N1 S-FLU vaccine induced weaker BAL
and stronger tracheobronchial lymph node responses and a lesser reduction in viral titer. We conclude that local cellular immune
responses are important for protection against influenza A virus infection, that these can be most efficiently induced by aerosol
immunization targeting the lower respiratory tract, and that S-FLU is a promising universal influenza vaccine candidate. The
Journal of Immunology, 2016, 196: 5014–5023.
I
nfluenza A virus (IAV) infection is a global health threat
to livestock and humans, causing substantial mortality and
morbidity. Pandemic and avian-like H1N1 and H3N2 IAV
are endemic in pigs and humans in addition to H1N2 in pigs. The
human pandemic 2009 H1N1 strain is also found in pigs, and
human viruses or human-origin gene segments frequently adapt to
transmit efficiently in pigs. Thus, pigs play a critical role in the
emergence and epidemiology of novel IAV.
Apart from the economic loss to farmers attributable to IAV
infections of pigs, the generation of new reassortant strains of IAV
poses a zoonotic threat to humans. Immunization is a cost-effective
control measure to combat influenza infection, but the rapid
evolution of the virus is a major obstacle. Conventional inactivated
IAV vaccines are strain specific and protection correlates with the
presence of neutralizing Ab. However, IAV infection and live at-
tenuated viral vaccines have been shown to induce a degree of
cross-protection in several species (1), suggesting that it may be
possible to develop an effective “universal vaccine” for use in pigs
and humans.
Influenza virus in which the hemagglutinin (HA) signal se-
quence is suppressed (S-FLU) is a candidate universal vaccine.
Suppression of the signal sequence limits expression of the viral
encoded HA protein to the cytosol. The HA protein coating
the S-FLU virus is provided from a transfected complementing
cell line by pseudotyping (2), and is expressed from a codon-
optimized cDNA lacking 59 and 39 untranslated regions of the
viral RNA. This design allows infection by the vaccine virus to
occur once only, resulting in attenuation. Replication of vaccine
in the lung or nose is prevented, but all of the conserved viral
proteins are expressed in the cytosol of S-FLU–infected cells for
optimal Ag presentation (3).
Immunization with S-FLU initiates broadly reactive cell-
mediated immune responses to conserved viral Ags shared by
all influenza viruses, which limit viral replication in the lungs of
mice and ferrets even when heterologous challenge IAVare used (2,
4). Neutralizing Ab is not induced.
In this study, we tested the effect of S-FLU–expressing pan-
demic origin H1 or H5 HA on viral load and pathology after
challenge with IAV-expressing homologous or heterologous HA
in pigs.
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Materials and Methods
S-FLU vaccine and influenza challenge virus
The design and production of S-FLU, that is, [S-eGFP/N1(Eng)].H1(Eng),
have been described previously (2). We used two vaccines, H1 and H5
S-FLU. H1 S-FLU expresses the HA and neuraminidase (NA) of the
A/England/195/2009(pandemic [pdm]H1N1) (N1 http://www.ncbi.nlm.
nih.gov/nuccore/GQ166659 and surface H1 HA http://www.ncbi.nlm.nih.
gov/nuccore/237689564) and internal protein genes of PR8. H5 S-FLU ex-
presses the HA of the highly pathogenic avian influenza virus (HPAIV)
A/Vietnam/1203/2004 (H5N1 clade 1, VN/04) with the NA and internal
protein genes of PR8 (4). The H5 HA cDNAwas codon optimized and the
polybasic site was replaced with a trypsin cleavage site.
The pig isolate of A/Swine/England/1353/09(pdmH1N1) (A/Sw/Eng/
1353/09) was provided by Dr. Sharon Brookes (Animal and Plant Health
Agency, U.K.). Virus stocks were propagated in the allantoic cavities of 9- to
11-d-old embryonated specific pathogen-free hens’ eggs and used for viral
challenge. For all serological and immunological assays the virus was
propagated in Madin–Darby canine kidney (MDCK) cells.
Animals and immunization
All experiments were approved by the ethical review processes at the
Pirbright Institute and the University of Bristol, according to the U.K.
Animal (Scientific Procedures) Act 1986.
Twenty-four twelve-week-old Landrace cross female pigs were obtained
from a commercial high health status herd. Pigs were screened for absence
of influenza A infection by matrix gene real-time RT-PCR and for Ab-free
status hemagglutination inhibition using four swine influenza virus Ags.
Pigs were randomly divided into four groups of six and immunized as fol-
lows: 1) control received 4 ml DMEM, 0.1% (w/v) BSA, and 13 penicillin
and streptomycin intratracheally (i.t.), 2) H1 S-FLU was administered i.t. at
23 107 tissue culture–infective dose (TCID)50 in 4 ml (H1 i.t.), 3) H1 S-FLU
was administered by aerosol (aer) by delivering ∼6.853 106 TCID50 in 1 ml
(H1 aer), and 4) H5 S-FLU was administered i.t. at 8 3 107 TCID50 in 4 ml
(H5 i.t.). The animals received an identical booster immunization 28 d later.
For i.t. immunization, following sedation, a 20-gauge needle was inserted
through the skin and wall of the trachea cranial to the sternum and for aerosol
immunization an InnoSpire Deluxe Philips Respironics nebulizer was fixed to
a small-sized anesthetic mask held over the animal’s nose and mouth. The
aerosol delivery process was designed to deliver 6.853 106 TCID50, although
the actual retained dose in the lungs cannot be measured directly. However,
we have determined that the nebulization process results in between 20 and
50% loss of viability of either S-FLU or the challenge virus, which means
that the actual dose of viable S-FLU administered by aerosol is lower.
For logistical reasons, two influenza virus challenges were performed, with
half of the animals challenged at 31 d postboost (dpb) and the remainder at
45 dpb. Pigs were rehoused so that each challenge pen contained one animal
from each immunization group. Animals were challenged intranasally with
63 106 50% egg infectious dose, equivalent to 1.53 105 PFU/pig of A/Sw/
Eng/1353/09. Two milliliters was administered to each nostril using a mu-
cosal atomization device (MAD300; Wolfe Tory Medical).
Pathological and histopathological examination of lungs
Animals were humanely killed 3 d postchallenge (dpc) with an overdose of
pentobarbital sodium anesthetic. The lungs were removed and digital images
taken of the dorsal and ventral aspects. Macroscopic pathology scoring was
performed blind at the University of Bristol using ImageJ v1.46r software
(National Institutes of Health) to determine the percentage of the total surface
area of the lung (dorsal and ventral aspects) affected by consolidation.
Lung tissue samples were collected into 10% neutral buffered formalin
for routine histological processing (University of Bristol). Formalin-fixed
tissues were paraffin wax embedded and 5-mm sections were cut and
then stained with H&E.
Microscopic changes in the sections of lung were scored by a veterinary
pathologist blinded to the treatment group. Five parameters were each
scored on a 5-point scale of 0–4 and then summed to give a total slide score
ranging from 0 to 20. Scoring criteria (Supplemental Table I) were based
on a previously published method (5) with modifications. In cases where
more than one lung sample was taken from an individual pig (e.g., lesion
and nonlesion sites), the section with the highest composite score was used
for subsequent statistical analysis. In these cases, this always corresponded
to a sample containing a lung lesion that was visible on gross examination.
Tissue sample processing
Two nasal swabs (one per nostril) were taken at 0, 1, 2, and 3 dpc. The swabs
were placed into 2ml virus transport medium comprising tissue culture medium
199 (Sigma-Aldrich) supplemented with 25 mM HEPES, 0.035% sodium
bicarbonate, 0.5% BSA, penicillin, streptomycin, and nystatin, vortexed, centri-
fuged to remove debris, and stored at 280˚C for subsequent virus titration.
Serum and citrate anticoagulated blood samples were collected at the
start of the study (prior to immunization), at days 0, 7, 13, and 28 dpb and
0 and 3 dpc. Citrate blood samples were diluted 1:1 in PBS before density
gradient centrifugation at 1200 3 g for 30 min over Histopaque 1.083g/ml
(Sigma-Aldrich). PBMCs were harvested from the interface, washed, and
RBCs were lysed with ammonium chloride lysis buffer, washed again, and
cryopreserved in FCS (Life Technologies) with 10% DMSO (Sigma-Aldrich).
Bronchoalveolar lavage (BAL) was collected from the entire right lung
lobe with 150 ml virus transport medium (described above). BAL cells were
isolated by centrifugation of the lavage fluid at 800 3 g for 15 min. The
supernatant was removed, aliquoted, and frozen for Ab analysis, whereas
the cell pellet was washed in PBS and filtered through a 70-mm cell
strainer and cryopreserved.
Tracheobronchial lymph nodes (TBLN) were dissected out. TBLN cells
were dissociated into a single-cell suspension with the gentleMACS Octo
dissociator (Miltenyi Biotec, Woking, U.K.), using C tubes (Miltenyi
Biotec) with 3 ml RPMI 1640. The single-cell suspension was filtered twice
using a 70-mm cell strainer, washed, and RBCs were lysed. Cells were
washed again and cryopreserved.
The accessory lung lobes were dissected out and frozen at 280˚C for
subsequent virus titration. The whole lobe was homogenized using the
gentleMACS Octo dissociator, the homogenate was clarified by centrifu-
gation, and supernatant was used for virus titration.
Virus titration
Viral titers in nasal swabs and the lung accessory lobe were determined
by plaque assay on MDCK cells. Samples were 10-fold serially diluted and
100 ml was overlaid on confluent MDCK cells in 12-well tissue culture
plates. After 1 h, the plates were washed and 2 ml 2% agarose/medium
(1:3) was overlaid. Plates were incubated at 37˚C for 48 h and plaques
visualized using 0.1% crystal violet.
Ab ELISA, HA inhibition, and microneutralization assay
Influenza-specific Ab titers in serum and BAL fluid were determined by HA
inhibition (HAI) using standard protocols (6). Briefly, H1 HAI Ab titers
were determined using 0.5% chicken RBCs and A/Sw/Eng/1353/09 at a
concentration of 4 HA units/ml.
Neutralizaing Ab titers were determined in serum and BAL fluid using a
microneutralization assay as described in the WHO Manual on Animal
and Influenza Diagnosis and Surveillance. Briefly, samples were diluted
10-fold and heat inactivated at 56˚C for 30 min, and further serially diluted
2-fold in PBS. Samples were then incubated with 4 3 104 PFU/ml
A/swine/England/1353/09(pdmH1N1) in serum-free DMEM for 1 h at
37˚C in 5% CO2. The virus/sample mix was then added onto confluent
MDCK cells in a 96-well plate and incubated at 37˚C in 5% CO2. After 1 h,
the plates were washed and overlaid with serum-free DMEM containing
2 mg/ml TPCK trypsin. Plates were incubated at 37˚C for 48 h and cyto-
pathic effect was visualized using 0.1% crystal violet. Titers were deter-
mined as the final dilution of serum that prevents cytopathic effect on
MDCK cells following incubation with virus.
The IgG and IgA ELISAs were performed in 96-well ELISA plates
(BD Biosciences) coated with a preoptimized concentration of A/swine/
England/1353/09(pdmH1N1). Two-fold dilutions of BAL fluid samples
were added starting from 1:2 dilution. Binding of Abs was detected using
preoptimized concentrations of polyclonal goat-anti pig IgG HRP or IgA-
HRP (AbD Serotec) and tetramethylbenzidine substrate (BioLegend). Ab
values were expressed as endpoint titers defined as the highest dilution at
which the OD was higher than twice the background OD.
IFN-g ELISPOT
Frequencies of IFN-g secreting in PBMCs, BAL, and TBLN cells were
determined by ELISPOT using either fresh or cryopreserved cells.
MultiScreen-HA ELISPOT plates (Merck Millipore) were coated with
0.5 mg/ml anti-pig IFN-g (clone P2G10; BD Pharmingen) in carbonate
buffer and incubated at 4˚C overnight. The plates were washed five times
in PBS and blocked using 4% (w/v) milk powder in PBS for 2 h. After five
washes in PBS, 53 105 cells were seeded in triplicate wells and stimulated
with either live MDCK cell–grown A/Sw/Eng/1353/09 (multiplicity of
infection [MOI] of 6), medium control, or 10 mg/ml Con A (Sigma-
Aldrich). Plates were incubated overnight or for 40 h at 37˚C in a 5%
CO2 incubator, depending on whether fresh or frozen cells were used, fol-
lowed by washes with PBS, 0.05% Tween 20, and addition of 0.25 mg/ml
anti-pig biotinylated IFN-g detection Ab (clone P2C11; BD Pharmingen).
Plates were incubated for 2 h at room temperature, washed five times,
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and streptavidin–alkaline phosphatase (Invitrogen) was added for a further
1 h at room temperature. Spots were visualized using an alkaline phos-
phatase substrate kit (Bio-Rad) and the reaction was stopped using tap
water. Immunospots were counted using the AID ELISPOT reader (AID
Autoimmun Diagnostika). Results were expressed as number of IFN-g–
producing cells per 106 cells after subtraction of the average number of
IFN-g+ cells in medium control wells.
Flow cytometry
Cryopreserved mononuclear cells from blood, TBLN, and BAL were thawed
and stimulated for 12 h at 37˚C with live MDCK cell–grown strain A/Sw/
Eng/1353/09 (MOI of 6 for BAL and PBMCs, MOI of 0.6 for TBLN) or
MDCK cell mock supernatant as control. GolgiPlug (BD Biosciences) was
added according to the manufacturer’s instructions for a further 5 h before
intracellular cytokine staining. Cells were stained for surface markers with
CD3ε-PeCy5 PPT3 (AbCam), biotinylated CD4 clone MIL17 (in-house),
with secondary streptavidin-allophycocyanin (SouthernBiotech), CD8a-
FITC MIL12 (AbD Serotec), and near-IR fixable Live/Dead stain (Invi-
trogen). Cells were permeabilized using Cytofix/Cytoperm (BD Biosciences)
as per the manufacturer’s instructions before intracellular staining with IFN-
g–PE P2G10 (AbD Serotec) and cross-reactive anti-human TNF-a–Pacific
Blue Mab11 (BioLegend). Samples were fixed in 1% paraformaldehyde
before analysis using an LSRFortessa instrument (BD Biosciences).
Data were analyzed using FlowJo v10 (Tree Star), and fluorescence
minus one primary Ab controls were used to set gates. Samples were batch
gated (Supplemental Fig. 1) on lymphocytes based on side scatter area/
forward scatter area, followed by single cells on forward scatter height/
forward scatter area. Live CD3+ cells were analyzed for expression of CD4
and CD8a. Boolean gating was used to determine the levels of IFN-g and
TNF-a expression in CD8ahi, CD4CD8a double-positive, and CD4 T cell
subsets. Postcytometric multivariate data analysis was performed using
SPICE version 5.3 (http://exon.niaid.nih.gov.).
Statistical analysis
One-way or two-way ANOVA with a Dunnett posttest for multiple com-
parisons were used to compare immunized groups to the control group, and
analysis was performed using GraphPad Prism 6. A general linear model
(GLM), together with Tukey honestly significant difference and least
significant difference post hoc tests, was used to identify any significant
differences between groups for individual variables. For pen and batch,
when p . 0.2, the variable was excluded from the GLM in a stepwise
fashion. Samples taken during multiple days were analyzed using a re-
peated measures GLM. A nonparametric Freidman rank test was used
when it was not possible to transform data to normality. A principal
component analysis was performed using 17 factors (including virus titer,
ELISPOT, pathology, and flow cytometry results) to explain overall vari-
ation between groups. Statistical analysis was performed using The R
Project for Statistical Computing (version 3.0.1) (http://www.r-project.org/),
IBM SPSS statistics software (version 21.0), and the GGobi data visuali-
zation system (version 2.1.10a) (http://www.ggobi.org/).
Results
Pulmonary immunization with S-FLU reduces viral load in
nasal swabs and lungs
S-FLU has previously been shown to protect mice and ferrets
against homologous and heterologous IAV challenge, and it has
been demonstrated that to confer protection, the vaccine needs to be
delivered to the lung (2, 4). We therefore administered S-FLU
either i.t. or by aerosol with a nebulizer to reach the lower re-
spiratory tract (LRT) of the pigs. We used two S-FLU vaccines:
H1 S-FLU expressing the HA and NA of A/England/195/2009
(pdmH1N1), and H5 S-FLU expressing the HA of the highly
pathogenic avian influenza virus A/Vietnam/1203/2004(H5) and
N1 from A/PR/8/34. Groups of six pigs were immunized with two
doses of H1 S-FLU i.t. (H1 i.t.) or by aerosol (H1 aer) or with H5
S-FLU i.t. (H5 i.t.); the control group received medium i.t. (con-
trol). Because of the different viral titers of the H1 and H5 S-FLU
vaccine stocks and different delivery routes, different doses of the
viruses were administered. H5 i.t. animals received 83 107 TCID50,
and the H1 aer group received a lower dose of ∼6.853 106 TCID50.
Most likely the dose actually received was even lower owing to
losses during the aerosolization and administration procedure.
Animals were challenged with the swine pdm09 strain A/Sw/
Eng/1353/09 at either 31 or 45 d after the second immunization
and euthanized 3 dpc to determine the effect of immunization at the
peak of virus replication. Despite immunization with .1 log less
H1 S-FLU, the pigs immunized by the aerosol route showed the
most efficient reduction of challenge virus in the nasal swabs at 1,
2, and 3 dpc (Fig. 1A). H1 S-FLU administered i.t. significantly
reduced viral shedding at 2 and 3 dpc (p = 0.001), whereas H5
S-FLU reduced viral shedding at 2 dpc (p = 0.016) and completely
prevented shedding in two individual animals at 3 dpc (Fig. 1A).
Aerosol administration of H1 S-FLU also significantly reduced the
viral titer in the accessory lobe of the lung (p = 0.006) (Fig. 1B).
No ill effects were observed in any of the pigs immunized with H1
or H5 S-FLU by either method of administration. Gross pathology
after viral challenge was minimal in most immunized animals;
however, the control group contained two individuals with severe
gross pathology (Fig. 1C). Most lung sections had total scores of#4
of a maximum score of 20, showing that there were only very subtle
histopathological changes. The pigs with the highest scores be-
longed to the control or to the H5 IT treatment groups (Fig. 1D), but
no significant difference between groups was detected. In addition
to the parameters scored, several lung sections showed moderate
levels of hemorrhage (data not shown) that was considered most
likely to be a postmortem artifact. Furthermore, collapse of alveolar
spaces frequently made assessment of alveolar septal thickness
difficult. However, these issues simply highlight amendments that
can be considered for sample collection for future studies.
These results indicated that administration of S-FLU in pigs
reduced the viral load in nasal swabs and lungs after closely
matched viral challenge and that this was most efficiently induced
by aerosol administration. H5 S-FLU reduced the viral load in
nasal swabs and lung following heterologous viral challenge, but
this was significant in nasal swabs only at 2 dpc.
Influenza-specific immune responses in PBMCs
As the analysis of samples from pigs challenged at days 31 and 45
did not reveal any significant differences (Fig. 1), for simplicity in
presentation the results of the immunological assays carried out on
pigs challenged on both days have been amalgamated.
Because most commercial vaccines used to control influenza virus
elicit a strong Ab response in the host, we first determined whether the
reduced viral replication after S-FLU immunization resulted from a
humoral immune response. HAI andmicroneutralization titers in serum
and BAL fluid of all immunized groups were comparable with un-
immunized controls at 3 dpc (Table I), consistent with previous studies
showing lack of neutralizing Ab responses following S-FLU immu-
nization of mice and ferrets (2, 4). Influenza-specific IgG and IgAwere
also quantified by ELISA in BAL fluid samples at 3 dpc and similarly
very low endpoint titers for IgG and IgA were detected (Table I).
We next determined average influenza-specific T cell responses
in PBMCs by IFN-g ELISPOT at 0 and 3 dpc. All S-FLU–
immunized groups showed a virus-specific response to the chal-
lenge pdmH1N1 virus of ∼30–60 spot-forming cells (SFC) per
106 cells just before the challenge (0 dpc), indicating that all an-
imals had been immunized successfully. H5 i.t. immunized ani-
mals, which showed the strongest T cell response to A/Sw/Eng/
1353/09 (p = 0.001), responded equally well to stimulation in vitro
with H1 S-FLU or H5 S-FLU vaccine constructs, whereas H1 i.t.
and H1 aer animals made minimal responses to H1 S-FLU or
H5 S-FLU (Fig. 2A). At 3 dpc the number of SFC following
pdmH1N1 stimulation declined in all immunized groups, most
likely due to the migration of influenza-specific PBMCs to the
lung. Intracellular cytokine staining of PBMCs at 3 dpc shows the
highest IFN-g and TNF-a responses in the H5 i.t. group (Fig. 2B).
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Taken together, these data show that the magnitude of the re-
sponse to IAV in peripheral blood, measured either as number of
IFN-gN or TNF-secreting cells, does not correlate with reduction
of viral load in nasal swabs or the accessory lung lobe. It is not
clear why PBMCs from the H1 i.t. and H1 aer–immunized animals
do not respond in vitro to stimulation with H1 S-FLU or H5
S-FLU, whereas H5 i.t. immunized animals do, but this may be
related to the higher dose of H5 S-FLU administered.
BAL and TBLN influenza-specific responses
We next measured the local influenza-specific immune responses
in cells from BAL and TBLN, the main draining lymph nodes of
the lungs. H1 aer immunization induced the highest numbers of
IFN-g–secreting cells in the BAL (∼200 SFC per 106 cells, p =
0.001), whereas a much lower response occurred in the H5 i.t. im-
munized animals and none in the H1 i.t. and control groups (Fig. 3A).
Because it has been suggested that cells simultaneously pro-
ducing IFN-g, IL-2, and TNF-a may provide optimal effector
function and protection against viral infections (7), we defined the
proportions of bifunctional cells in our immunized animals. We
performed intracellular staining for IFN-g and TNF-a on BAL
cells stimulated with A/Sw/Eng/1353/09. H1 aer immunization
induced the strongest, single IFN-g responses by CD8 and
CD4CD8 cells (0.41% in CD8 and 0.32% in CD4CD8 cells),
followed by the H5 i.t. regimen (Fig. 3B, 3C). The proportion of
cells producing TNF-a was very low in all cell subsets, and nei-
ther TNF-a single-producing nor IFN-gTNF-a double-producing
cells differed between the groups (Fig. 3B–D). The pie charts
summarize the proportions of single and double cytokine-
producing cells in the BAL. The H1 aer and H5 i.t. regimes
appear to induce different proportions of single or double
cytokine-producing influenza-specific cells compared with H1
i.t. and controls. However, H1 i.t. and controls induced very few
Ag-specific cells so that interpretation of these data requires cau-
tion. Nevertheless, H1 aer immunization induced greater numbers
of IFN-g single producers in all cell subsets.
TBLN responses differ from those in the BAL. H5 i.t. immu-
nization induced the strongest IFN-g ELISPOT response followed
by the H1 aer regimen (Fig. 4A). Similarly, the H5 i.t. regimen
induced the significantly highest CD4CD8 IFN-g–producing
cells as determined by intracellular cytokine staining staining
(p = 0.009) followed by the H1 aer regimen (p = 0.047) (Fig. 4C).
FIGURE 1. S-FLU reduces viral load in nasal swabs and lung. Pigs were immunized twice 28 d apart with either H1 S-FLU by the i.t. route (H1 i.t.), by aerosol
(H1 aer), or with H5 S-FLU given i.t. (H5 i.t.). Animals were challenged with A/Sw/Eng/1353/09 at 31 (filled symbols) or 45 (open symbols) dpb. Nasal swabs
were taken at 0, 1, 2, and 3 dpc and pigs were sacrificed at 3 dpc. Viral titers in the nasal swabs (A) and accessory lobe of the lungs (B) were determined by plaque
assay and lungs were assessed for appearance of gross (C) and microscopic (D) pathological lesions. Each datum point represents an individual within the indicated
group and bars represent the mean. *p , 0.05 versus control group determined using one-way ANOVA with a Dunnett test for multiple comparisons. I.T., i.t.
Table I. Serum and BAL fluid A/swine/1353/09(pdmH1N1)–specific HAI, MN, IgG, and IgA titers
Group
Serum BAL Fluid BAL Fluid 3 dpc
HAIa MNb
HAIa MNb
ELISAc
0 dpc 3 dpc 13 dpb 3 dpc (3 dpc) (3 dpc) IgG IgA
Control 8.0 6 0.0 7.3 6 1.5 ,10 ,10 4.0 6 0.0 ,10 0.8 6 1.1 0.0 6 0.0
H1 i.t. 9.6 6 3.2 14.7 6 8.5 ,10 ,10 5.3 6 1.9 ,10 3.6 6 7.0 2.4 6 2.2
H1 aer 11.2 6 4.0 14.7 6 3.0 ,10 ,10 5.6 6 2.0 ,10 3.0 6 7.0 2.0 6 2.0
H5 i.t. 8.0 6 0.0 10.0 6 4.5 ,10 ,10 12.0 6 4.0 ,10 8.0 6 8.8 2.0 6 1.3
aHAI titers were determined in serum at 0 and 3 dpc and BALF after sacrifice at 3 dpc using 4 HA units of A/Sw/Eng/1353/09 virus. Results shown are the mean of six
animals 6 SD. As a positive control, serum from pigs immunized with commercial A(H1N1)pdm09 vaccine Pandemrix (GlasxoSmithKline) and challenged with A/England/
195/09(pdmH1N1) virus as described (6) was used and gave a titer of 2048.
bMN titers were determined in serum at 13 dpb and 3 dpc and BALF after sacrifice at 3 dpc using 100 PFU A/Sw/Eng/1353/09 virus. Results shown are the mean of six
animals. Serum and BALF collected from A/Sw/Eng/1353/09 virus–infected pigs at 14 dpc were used as controls with both giving a titer of 80.
cIgG and IgA titers in BALF after sacrifice at 3 dpc. Results shown are the mean of six pigs 6 SD. As a positive control, BALF collected from A/Sw/Eng/1353/09 virus–
infected pigs at 14 dpc was used and gave an endpoint titer of 1024 for IgA and 128 for IgG.
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TNF-a production was higher compared with the BAL, although no
differences between the groups were detected in the proportion of
single TNF-a– or double TNF-aIFN-g–producing cells. As for
BAL, the pie charts show that the best protected H1 aer group had
the highest proportion of IFN-g single-producing cells (Figs. 4B–D).
In summary, the most protective H1 aer immunization induces a
strong BAL and weaker TBLN response to IAV. These responses
consist of cells with high amounts of intracellular IFN-g, which
correlate with and may account for their protective efficacy.
S-FLU may have the potential to be a candidate universal
vaccine
Principal component analysis (PCA) was used to reduce a large
number of original variables to a smaller number of undefined,
underlying variables that are responsible for the variation in the
data. The first principal component, PC1, could explain 23.1% of
the total variation between pigs (Fig. 5A). A general linear model
showed that PC1 was significantly associated with immunization
status (p = 0.0014). In particular, the post hoc test revealed sig-
nificant differences between the control and most of the immu-
nization groups (H1 aer, p = 0.0009; H5 i.t., p = 0.0012). A second
component, PC2, explained a further 14.9% of the variation and
could be theorized to be associated with route of administration,
although there was no significant difference between the aerosol
and i.t. delivery routes (data not shown). Because of missing data
points, it was not possible to obtain a full set of principal com-
ponents for four pigs (one in each treatment group).
The variables used for the PCA were assigned to one of four
groups relating to gross pathology, viral titer, histopathology, or
immune response. Fig. 5B shows the PCA loadings for each of
these variables. The loadings explain how much variation within a
particular variable can be assigned to a principal component.
Three distinct clusters can be identified; viral titer and histopa-
thology cluster together in the same quadrant, suggesting that
there is an association with viral load and histopathological signs.
Interestingly, IFN-g production by CD4+ T cells in BAL also
appears in this quadrant. Although gross pathology and histopa-
thology appear in different quadrants, they do not directly oppose
each other, suggesting that there is still some level of association
between the two variables.
Considering Fig. 5A and 5B together, the PCA analysis shows
that virus titer and histopathology scores were highest in the control
group and lowest in the H1 aer group. Note that the H5 i.t. group
also had a reduction in viral load and histopathology. Additionally,
the figures show that the strongest immune response was seen in the
H5 i.t. group, closely followed by the H1 aer group. This may be
explained by the heterologous challenge virus used in the H5 i.t.
group, as opposed to homologous challenge. The H1 i.t. and H1 aer
groups also had lower gross pathology scores than did the control
and H5 i.t. groups. Consistent with the previous analyses on indi-
vidual variables, it appears that the H1 aer vaccination was most
effective at reducing viral load and histopathological and gross
pathological signs, as well as inducing an effective immune re-
sponse to challenge with a homologous virus.
Discussion
Abundant evidence in humans and animals shows that natural
influenza virus infection or immunization with live attenuated
influenza viruses can induce a degree of cross protection (1, 8, 9).
Cross-reactive CD4 and CD8 T cells or anti-HA stem Abs have
been postulated as correlates of this cross protection in humans,
but vaccines currently in use induce these responses poorly. In the
present study, we have used a novel candidate universal vaccine,
S-FLU, based on the suppression of HA signal sequence. S-FLU
has the advantage of inducing an immune response to all viral
components, but without replication of virus or danger of reas-
sortment of HA viral RNA into seasonal influenza, making im-
munization directly to the site of infection safe.
Our data show that immunization with S-FLU–expressing
H1 HA (H1 S-FLU) reduces the viral load in nasal swabs and
lungs after challenge with the closely matched pdmH1N1 virus
strain. The reduction of viral load was greatest after aerosol
FIGURE 2. Cytokine responses in PBMCs following S-FLU immunization. Pigs were immunized twice 28 d apart with either H1 S-FLU by the i.t. route
(H1 i.t.), by aerosol (H1 aer), or with H5 S-FLU given i.t (H5 i.t.). Animals were challenged with A/Sw/Eng/1353/09 and PBMCs isolated at 0 and 3 dpc.
(A) Numbers of IFN-g SFC were determined by ELISPOT following stimulation with the challenge virus, H1 S-FLU, or H5 S-FLU. (B) Flow cytometry
was used to quantitate the frequency of IFN-g– and TNF-a–producing cells within CD8hi, CD4+CD8+, and CD4+ after stimulation with A/Sw/Eng/1353/09.
Each datum point represents an individual within the indicated group. Results are representative of two independent experiments. **p , 0.005, ***p ,
0.0005 versus control group determined using two-way ANOVA with a Dunnett test for multiple comparisons. I.T., i.t.
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administration of S-FLU. Detectable neutralizing Ab was not
produced in S-FLU–immunized pigs. Rather, the reduction of
viral load in the H1 aer group correlated with the presence of IFN-
g–producing CD8 or CD4CD8 double-positive cells in the BAL.
CD4CD8 double-positive cells in pigs are activated memory CD4
cells (10), meaning S-FLU appears capable of inducing both CD4
and CD8 memory, both of which have been shown to be important
in protective immunity to influenza (11–13). H5 i.t. immunization
induces a much weaker BAL response, even though a higher dose
of virus was administered, but stronger TBLN and PBMC re-
sponses. These results suggest that the effects of priming by
aerosol and i.t. administered vaccines differ. The higher TBLN
response and lower BAL response after i.t. immunization suggest
either that priming by this route may have slower kinetics than
FIGURE 3. S-FLU immunization induces influenza-specific T cell responses in the BAL. Pigs were immunized twice 28 d apart with either H1 S-FLU
i.t. (H1 i.t.), by aerosol (H1 aer), or with H5 S-FLU i.t. (H5 i.t.). Animals were challenged with A/Sw/Eng/1353/09 and sacrificed at 3 dpc. Cells were
stimulated with the challenge virus. (A) Numbers of IFN-g–secreting cells were determined by ELISPOT in the BAL 3 dpc. Flow cytometry was used to
quantitate the frequency of IFN-g– and TNF-a–producing cells (graphs) and the qualitative bifunctional cytokine response (pie charts) within CD8hi (B),
CD4+CD8+ (C), and CD4+ (D). Each datum point represents an individual within the indicated group. Results are representative of two independent
experiments. ***p = 0.001 versus control group determined using two-way ANOVA with a Dunnett test for multiple comparisons. I.T., i.t.
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aerosol immunization so that responding cells are still in the
draining nodes at the time of euthanasia or that cells primed by
this route do not acquire homing molecules allowing them to
enter the alveolar spaces. It is also possible that the HA and NA
molecules expressed on different S-FLUs may influence which
cells within the respiratory tract can be infected. This in turn
might influence the magnitude and nature of the immune re-
sponse. Further experiments are required to define more clearly
distribution of S-FLU delivered to pigs by aerosol or to the upper
trachea and the properties of the Ag-specific cells induced. Our
preliminary data (not shown) indicate that S-FLU administered
intranasally did not induce lung immune responses or reduce viral
load. Finally, we have recently shown that S-FLU can induce
inhibitory Abs to the encoded NA in mice (T. Powell, P. Rijal,
K.-Y. Huang, R. McEwen-Smith, H. Byun, M. Hardwick,
L. Schimanski, R. Daniels, and A. Townsend, submitted for
publication), so it is possible that the homologous immunization
with H1N1 S-FLU induced a protective anti-N1(Eng) response.
This is less likely with the H5N1 S-FLU, which encoded a dis-
tantly related N1 sequence from A/PR/8/34.
FIGURE 4. Cytokine responses in TBLN to influenza virus. Pigs were immunized twice 28 d apart with either H1 S-FLU i.t. (H1 i.t.) or by aerosol (H1
aer) or H5 S-FLU i.t (H5 i.t.). Animals were challenged with A/Sw/Eng/1353/09. (A) Numbers of IFN-g–secreting cells in the TBLN at 3 dpc were
determined by ELISPOT. Flow cytometry was used to quantitate the frequency of IFN-g+ and TNF-a+ cells (graphs) and the qualitative bifunctional
cytokine response (pie charts) within CD8hi (B), CD4+CD8+ (C), and CD4+ (D). Each datum point represents an individual within the indicated group.
Results are representative of two independent experiments. *p = 0.05, **p = 0.0085 versus control group determined using two-way ANOVAwith a Dunnett
test for multiple comparisons. I.T., i.t.
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Recent overwhelming evidence shows that immunization or
infection via the respiratory tract results in generation of lung-
resident memory T cells, which are much more numerous than
previously thought and are critical for protection (14–16). These
lung-resident T cells are phenotypically different from their
peripheral blood counterparts and respond more vigorously to
respiratory viruses, thus providing additional protection against
infection. Further investigation will be needed to reveal the dis-
tribution within the lungs of memory cells induced by different
methods of immunization and determine whether the BAL cells
FIGURE 5. (A) PCA plot of response to swine influenza infection. PC1 explained 23.1% of the total variation between pigs and PC2 explained a further
14.9% of the variation. Treatment groups are represented by different symbols and each point represents an individual pig. (B) PCA loadings for each
individual input variable. Three distinct clusters can be observed comprised of gross pathology, virus load and histopathology, and immune response. d,
days postchallenge; ELI, ELISPOT; I.T., i.t.; LN, lymph node; NS, nasal swab; vt, viral titer.
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we detect in H1 aer–immunized pigs are part of the lung-resident
memory population.
The influenza-specific responses in our S-FLU–immunized
animals were detectable up to 45 dpb but neither the frequency of
IFN-g–secreting cells nor the presence of multifunctional cells in
the blood correlated with reduction of viral burden in nasal swabs
or lungs. In humans, specific subsets of blood memory T cells with
specificity for conserved internal proteins of influenza virus have
been associated with protection against infection (11–13). Addi-
tional work may indicate whether such memory subsets exist in
pigs and are induced by immunization with S-FLU. Influenza-
specific cross-reactive CD8 T cells are also detectable in the
lungs and persist for at least a year in mice and humans (14, 17).
Longer studies in pigs will be required to establish the persistence
of memory in this species and whether lung immune responses
correlate with protective immunity during an extended period.
Our experiments in pigs demonstrate that targeting the LRT by
aerosol is an efficient way to induce an immune response and to
reduce viral load. This is in agreement with earlier studies showing
that for optimum induction of protective T cell immune response in
mice and ferrets, virus infection of the lung is required, as opposed
to infection of the upper respiratory tract or other peripheral sites
(18–20). Aerosol delivery of H1 S-FLU (at least 4-fold less than
H1 S-FLU i.t. and ∼1 log less than H5 S-FLU i.t. administered
dose) induced a potent immune response in the BAL compared
with the i.t. route of administration and was the most efficient
in reducing viral load. A higher dose H5 i.t. immunization pro-
vided some degree of reduction of viral load after heterologous
pdmH1N1 challenge. However, our method of i.t. delivery to the
upper trachea clearly fails to immunize the lung efficiently and
therefore further studies using aerosol administration will be re-
quired to establish whether S-FLU provides a high degree of
heterologous as well as homologous protection in pigs. Similar
comparisons between i.t. and aerosol delivery have been per-
formed with adenoviral-vectored tuberculosis or Ebola vaccines in
nonhuman primates, and in both cases aerosol delivery offered
superior protection compared with other mucosal routes (21, 22).
Although aerosol delivery of measles vaccine has been suc-
cessfully deployed in humans (23, 24), to our knowledge this is
the first report of delivery of an influenza vaccine to pigs by
aerosol. Feng et al. (25) delivered a Mycoplasma hyopneumoniae
vaccine by aerosol to pigs, and although they showed that the
vaccine reached the LRT and induced local IgA, they did not
assess protection or T cell responses induced by the immuniza-
tion. Further studies will be required to develop practical devices
for aerosol immunization in the field, but our data provide proof
of principle that S-FLU can be efficiently delivered by aerosol to
a large animal, strongly suggesting that this would be a highly
efficient method of immunizing both pigs and humans against
influenza viruses.
Various live attenuated influenza vaccines (LAIV) have been
developed and shown to be effective when delivered to pigs
by the intranasal route (26–29). Loving et al. (29) used LAIV
temperature-sensitive polymerase mutants to show prevention of
viral shedding and transmission, but this did not correlate with Ab
titers in serum or mucosal secretions. At first sight this result
appears to contradict our finding that delivery of the vaccine to the
LRT is the most efficient means of inducing a protective immune
response. There are also other differences between the present
study and that of Loving et al. (29). They used much younger
(5 wk) and smaller animals and a different challenge virus (H3N2),
and the details of the method of intranasal administration are not
clear. Furthermore, no assays of T cell immunity were carried out so
that it is not possible to exclude the possibility that a lung immune
response was induced. Only head-to-head studies of different vac-
cines, together with assays of local and systemic immunity, will
reveal the factors underlying these apparent differences.
Vaccine-associated enhanced respiratory disease (VAERD) has
been reported after immunization with inactivated swine H1N2
vaccine followed by infection with pdmH1N1 and correlated with
the presence of anti-HA stem Ab (30). However, it has been
demonstrated that VAERD could not be induced after adminis-
tration of LAIV (5). This and our data showing lack of VAERD
after S-FLU immunization support the idea that mucosal admin-
istration of vaccines avoids this complication.
The licensed cold-adapted LAIV (FluMist) can induce cross-
protective immunity when delivered to the lung (2, 4, 31), but
not the upper respiratory tract of mice (20). However, there are
two barriers to delivering existing LAIV to the LRT. The first is
that delivery to the LRT of humans, although it may be the most
effective means to induce protective immunity, may be dangerous,
as LAIV retains some potential to replicate. Second, the viral RNA
encoding pandemic HA in the vaccine virus is capable of reas-
sortment with circulating seasonal viruses, with the potential to
render the latter highly virulent (32). In contrast, S-FLU should be
safe for aerosol administration to the lung because it cannot repli-
cate, nor can it donate, a viable HA gene to seasonal influenza.
Although understanding of immunity to influenza virus remains
incomplete, our experiments suggest an important role for local
lung immunity. Heterotypic immunity of the type induced by
S-FLU, which is predominantly T cell mediated, does not prevent
viral entry, but limits viral replication. Additional studies will be
required to test whether the reduction in viral load shown in these
studies is sufficient to block transmission and prevent disease.
Nevertheless, the best protected lungs showed the highest numbers
of Ag-specific cells in the BAL, indicating that local immunity in
the lung is an important mechanism by which universal vaccines
can confer protection. These data therefore have important im-
plications for the design of pig and human universal vaccines
against influenza. Challenges for the future will include the design
of immunization regimes and devices that can safely induce long-
lasting lung-resident memory in humans and livestock.
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